Document:

Exhibit 4.2

 

SECOND SUPPLEMENTAL INDENTURE

 

(Cherokee Statutory Trust I)

 

THIS SECOND SUPPLEMENTAL
INDENTURE dated as of June 29, 2018, is by and among Wilmington Trust Company, a Delaware trust company, as Trustee (herein,
together with its successors in interest, the “Trustee”), Ameris Bancorp, a Georgia corporation (the “Successor
Company”), and Hamilton State Bancshares, Inc., a Georgia corporation (the “Company”), under the Indenture referred
to below.

 

NOW, THEREFORE,
in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged by the parties hereto, the Trustee, the Company and the Successor Company hereby agree as follows:

 

PRELIMINARY STATEMENTS

 

The Trustee and the
Company, as successor by merger to Cherokee Banking Company (“CBC”), are parties to that certain Indenture dated as
of November 10, 2005, as supplemented by that certain Supplemental Indenture by and among the Trustee, the Company and CBC dated
as of February 17, 2014 (as so supplemented, the “Indenture”), pursuant to which CBC issued U.S. $3,093,000 of its
Fixed/Floating Rate Junior Subordinated Deferrable Interest Debentures due 2035 (the “Debentures”).

 

As permitted by the
terms of the Indenture, the Company, simultaneously with the effectiveness of this Second Supplemental Indenture, shall merge (referred
to herein for purposes of Article XI of the Indenture as the “Merger”) with and into the Successor Company with the
Successor Company as the surviving corporation. The parties hereto are entering into this Second Supplemental Indenture pursuant
to, and in accordance with, Articles IX and XI of the Indenture.

 

SECTION 1.  Definitions.
All capitalized terms used herein that are defined in the Indenture, either directly or by reference therein, shall have the respective
meanings assigned them in the Indenture except as otherwise provided herein or unless the context otherwise requires.

 

SECTION 2.  Interpretation.

 

		(a)	In this Second Supplemental Indenture, unless a clear contrary intention appears:

 

		(i)	the singular number includes the plural number and vice versa;

 

		(ii)	reference to any gender includes the other gender;

 

		(iii)	the words “herein,” “hereof” and “hereunder” and other words
of similar import refer to this Second Supplemental Indenture as a whole and not to any particular Section or other subdivision;

 

     

     

    

  

		(iv)	reference to any Person includes such Person’s successors and assigns but, if applicable,
only if such successors and assigns are permitted by this Second Supplemental Indenture or the Indenture, and reference to a Person
in a particular capacity excludes such Person in any other capacity or individually, provided that nothing in this clause (iv)
is intended to authorize any assignment not otherwise permitted by this Second Supplemental Indenture or the Indenture;

 

		(v)	reference to any agreement, document or instrument means such agreement, document or instrument
as amended, supplemented or modified and in effect from time to time in accordance with the terms thereof and, if applicable, the
terms hereof, as well as any substitution or replacement therefor, and reference to any note includes modifications thereof and
any note issued in extension or renewal thereof or in substitution or replacement therefor;

 

		(vi)	reference to any Section means such Section of this Second Supplemental Indenture; and

 

		(vii)	the word “including” (and with correlative meaning “include”) means including
without limiting the generality of any description preceding such term.

 

		(b)	No provision in this Second Supplemental Indenture shall be interpreted or construed against any
Person because that Person or its legal representative drafted such provision.

 

SECTION 3.   Assumption
of Obligations.

 

		(a)	Pursuant to, and in compliance and accordance with, Section 11.1 and Section 11.2 of the Indenture,
the Successor Company hereby expressly assumes the due and punctual payment of the principal of (and premium, if any) and interest
on all of the Debentures in accordance with their terms, according to their tenor, and the due and punctual performance and observance
of all of the covenants and conditions of the Indenture to be kept, performed, or observed by the Company under the Indenture.

 

		(b)	Pursuant to, and in compliance and accordance with, Section 11.2 of the Indenture, the Successor
Company succeeds to and is substituted for the Company, with the same effect as if the Successor Company had originally been named
in the Indenture as the Company.

 

		(c)	The Successor Company also succeeds to and is substituted for the Company with the same effect
as if the Successor Company had originally been named in (i) the Amended and Restated Declaration of Trust of the Trust, dated
as of November 10, 2005 (the “Trust Agreement”), as Sponsor (as defined in the Trust Agreement) and (ii) the Guarantee
Agreement, dated as of November 10, 2005 (the “Guarantee”), as Guarantor (as defined in the Guarantee).

 

    	 	2	 

     

    

  

SECTION 4.  Representations
and Warranties. The Successor Company represents and warrants that (a) it has all necessary power and authority to execute
and deliver this Second Supplemental Indenture and to perform the Indenture, (b) it is the successor of the Company pursuant to
the Merger effected in accordance with applicable law, (c) it is a corporation organized and existing under the laws of Georgia,
(d) both immediately before and after giving effect to the Merger and this Second Supplemental Indenture, no Default or Event of
Default, and no event which, after notice or lapse of time or both, would become an Event of Default, has occurred and is continuing
and (e) this Second Supplemental Indenture is executed and delivered pursuant to Section 9.1(a) and Article XI of the Indenture
and does not require the consent of the Securityholders.

 

SECTION 5. Conditions
of Effectiveness. This Second Supplemental Indenture shall become effective simultaneously with the effectiveness of the
Merger; provided, however, that:

 

		(a)	the Trustee shall have executed a counterpart of this Second Supplemental Indenture and shall have
received one or more counterparts of this Second Supplemental Indenture executed by the Successor Company and the Company;

 

		(b)	the Trustee shall have received an Officers’ Certificate stating that (i) this Second Supplemental
Indenture complies with the requirements of Article IX of the Indenture; and (ii) in the opinion of the signers, all conditions
precedent, if any, provided for in the Indenture relating to the Merger and this Second Supplemental Indenture have been complied
with;

 

		(c)	the Trustee shall have received an Opinion of Counsel to the effect that (i) all conditions precedent
provided for in the Indenture relating to the Merger and this Second Supplemental Indenture have been complied with; (ii) this
Second Supplemental Indenture complies with the requirements of Article IX of the Indenture and is authorized or permitted by,
and conforms to, the terms of Article IX of the Indenture; (iii) it is proper for the Trustee, under the provisions of Article
IX of the Indenture, to join in the execution of this Second Supplemental Indenture; and (iv) the Merger and the assumption by
the Successor Company under this Second Supplemental Indenture comply with the provisions of Article XI of the Indenture; and

 

		(d)	the Successor Company shall have duly executed and filed with the Secretary of State of the State
of Georgia a certificate of merger in connection with the Merger.

 

    	 	3	 

     

    

  

SECTION 6.   Reference
to the Indenture.

 

		(a)	Upon the effectiveness of this Second Supplemental Indenture, each reference in the Indenture to
“this Indenture,” “hereunder,” “herein” or words of like import shall mean and be a reference
to the Indenture, as affected, amended and supplemented hereby.

 

		(b)	Upon the effectiveness of this Second Supplemental Indenture, each reference in the Debentures
to the Indenture, including each term defined by reference to the Indenture, shall mean and be a reference to the Indenture or
such term, as the case may be, as affected, amended and supplemented hereby.

 

		(c)	The Indenture, as amended and supplemented hereby, shall remain in full force and effect and is
hereby ratified and confirmed.

 

SECTION 7.  Execution
in Counterparts. This Second Supplemental Indenture may be executed in any number of counterparts and by different parties
hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which
when taken together shall constitute but one and the same instrument.

 

SECTION 8.  Governing
Law; Binding Effect. This Second Supplemental Indenture shall be governed by and construed in accordance with the laws
of the State of New York and shall be binding upon the parties hereto and their respective successors and assigns.

 

SECTION 9.  The
Trustee. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency
of this Second Supplemental Indenture or the due execution thereof by the Company or the Successor Company. The recitals of fact
contained herein shall be taken as the statements solely of the Company or the Successor Company, and the Trustee assumes no responsibility
for the correctness thereof.

 

[Signatures on following page.]

 

    	 	4	 

     

    

  

IN WITNESS WHEREOF,
the parties hereto have caused this Second Supplemental Indenture to be duly executed as of the day and year first written above.

 

	 	HAMILTON STATE BANCSHARES, INC.
	 	 	 
	 	By:	/s/ Robert C. Oliver
	 	Name:  Robert C. Oliver
	 	Title:  Chief Executive Officer
	 	 	 
	 	AMERIS BANCORP
	 	 	 
	 	By:	/s/ Dennis J. Zember Jr.
	 	Name:  Dennis J. Zember Jr.
	 	Title:  Executive Vice President and Chief Operating Officer
	 	 	 
	 	WILMINGTON TRUST COMPANY, not in its individual capacity, but solely as Trustee
	 	 	 
	 	By:	/s/ Michael H. Wass
	 	Name:  Michael H. Wass
	 	Title:  Vice President

 

    	 	5EX-10.1

 Exhibit 10.1 
  

 
  

SHARE PURCHASE AGREEMENT 

dated as of June 29, 2018 

by and among 
 ATHENEX, INC.,

 and 
 PERCEPTIVE LIFE
SCIENCES MASTER FUND, LTD. 
  
  

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
		
	ARTICLE I	  			
		
	Purchase; Purchase Price; and Closings	  	 	 
	SECTION 1.1.	 	Purchase	  	 	1	 
	SECTION 1.2.	 	Purchase Price	  	 	2	 
	SECTION 1.3.	 	Closing	  	 	2	 
	SECTION 1.4.	 	Closing Conditions	  	 	2	 
		
	ARTICLE II	  			
		
	Representations and Warranties	  			
			
	SECTION 2.1.	 	Representations and Warranties of the Company	  	 	4	 
	SECTION 2.2.	 	Representations and Warranties of the Investor	  	 	13	 
		
	ARTICLE III	  			
		
	Covenants	  			
			
	SECTION 3.1.	 	Filings; Other Actions	  	 	15	 
	SECTION 3.2.	 	Expenses	  	 	16	 
	SECTION 3.3.	 	Confidentiality	  	 	16	 
	SECTION 3.4.	 	Representations and Warranties.	  	 	16	 
	SECTION 3.5.	 	Registration Statement.	  	 	17	 
		
	ARTICLE IV	  			
		
	Additional Agreements	  			
			
	SECTION 4.1.	 	Compliance with Laws	  	 	17	 
	SECTION 4.2.	 	Legend	  	 	17	 
	SECTION 4.3.	 	Indemnity	  	 	18	 
	SECTION 4.4.	 	Registration Rights	  	 	20	 
		
	ARTICLE V	  			
		
	Termination	  			
			
	SECTION 5.1.	 	Termination	  	 	20	 
	SECTION 5.2.	 	Effects of Termination	  	 	20	 

  
 ii 

							
	ARTICLE VI	  			
		
	Miscellaneous	  	 	 
	SECTION 6.1.	 	Survival	  	 	21	 
	SECTION 6.2.	 	Amendment	  	 	21	 
	SECTION 6.3.	 	Waivers	  	 	21	 
	SECTION 6.4.	 	Counterparts	  	 	21	 
	SECTION 6.5.	 	Governing Law	  	 	21	 
	SECTION 6.6.	 	Dispute Resolution	  	 	21	 
	SECTION 6.7.	 	Notices	  	 	22	 
	SECTION 6.8.	 	Entire Agreement, Etc	  	 	23	 
	SECTION 6.9.	 	Definitions	  	 	23	 
	SECTION 6.10.	 	Captions	  	 	25	 
	SECTION 6.11.	 	Severability	  	 	25	 
	SECTION 6.12.	 	No Third-Party Beneficiaries	  	 	25	 
	SECTION 6.13.	 	Public Announcements	  	 	25	 
	SECTION 6.14.	 	Specific Performance	  	 	26	 

 LIST OF EXHIBITS 
  

			
	Exhibit A:	  	Form of Officer’s Certificate from the Company
	Exhibit B:	  	Form of Legal Opinion
	Exhibit C:	  	Form of Registration Rights Agreement

  
 iii 

 INDEX OF DEFINED TERMS 

 

					
	Term	  	Location of Definition	 
	 Actions
	  	 	Section 2.1(m)	 
	 Affiliate
	  	 	Section 6.9(a)	 
	 Aggregate Purchase Price
	  	 	Section 1.2	 
	 Agreement
	  	 	Recitals	 
	 Anti-Money Laundering Laws
	  	 	Section 2.1(p)	 
	 Applicable Laws
	  	 	Section 2.1(o)	 
	 Basket
	  	 	Section 4.3(a)	 
	 Beneficially Own/ Beneficial Ownership
	  	 	Section 6.9(a)	 
	 Closing
	  	 	Section 1.3	 
	 Closing Date
	  	 	Section 1.3	 
	 Common Stock
	  	 	Recitals	 
	 Company
	  	 	Recitals	 
	 Company Indemnified Parties
	  	 	Section 4.3(b)	 
	 control/controlled-by/under common control
with
	  	 	Section 6.9(a)	 
	 Credit Agreement
	  	 	Section 1.4(a)	 
	 De Minimis Claim
	  	 	Section 4.3(a)	 
	 Disqualification Event
	  	 	Section 2.1(x)	 
	 e-mail
	  	 	Section 6.4	 
	 Encumbrances
	  	 	Section 2.1(a)	 
	 Environmental Laws
	  	 	Section 2.1(u)	 
	 Exchange Act
	  	 	Section 2.1(v)	 
	 Fundamental Representations
	  	 	Section 4.3(a)	 
	 GAAP
	  	 	Section 2.1(h)	 
	 Governmental Entity
	  	 	Section 1.4(a)	 
	 Governmental Order
	  	 	Section 1.4(a)	 
	 Group Companies
	  	 	Section 6.9(a)	 
	 Indemnified Party
	  	 	Section 4.3(c)	 
	 Indemnifying Party
	  	 	Section 4.3(c)	 
	 Information
	  	 	Section 3.3	 
	 Infringe
	  	 	Section 2.1(w)	 
	 Intellectual Property
	  	 	Section 2.1(w)	 
	 Investor
	  	 	Recitals	 
	 Investor Indemnified Parties
	  	 	Section 4.3(a)	 
	 knowledge of the Company/ Company’s knowledge
	  	 	Section 6.9(a)	 
	 License Agreements
	  	 	Section 2.1(w)	 
	 Losses
	  	 	Section 4.3(a)	 
	 Material Adverse Effect
	  	 	Section 6.9(a)	 
	 person
	  	 	Section 6.9(a)	 
	 Purchase Price Per Share
	  	 	Section 1.2	 
	 Purchased Shares
	  	 	Section 1.1	 
	 Registration Rights Agreement
	  	 	Recitals	 
	 Sanctioned Country
	  	 	Section 2.1(q)	 
	 Sanctions
	  	 	Section 2.1(q)	 

  
 iv 

					
	 SEC
	  	 	Section 2.1	 
	 SEC Documents
	  	 	Section 2.1	 
	 Securities Act
	  	 	Recitals	 
	 Trading D Trading Day ay
	  	 	Section 1.2	 
	 Transaction Documents
	  	 	Recitals	 
	 Transfer Agent
	  	 	Section 1.3	 
	 Warrant
	  	 	Recitals	 

  

  
 v 

 THIS SHARE PURCHASE AGREEMENT, dated as of June 29, 2018 (this
“Agreement”), is made by and between Athenex, Inc., a company incorporated under the laws of the State of Delaware (the “Company”) and Perceptive Life Sciences Master Fund, Ltd., a Cayman Islands exempted company
(the “Investor”). 
 RECITALS: 

A. The Investment. The Investor intends to subscribe for and purchase from the Company, and the Company intends to issue and sell to
the Investor, as an investment in the Company, the securities as described herein. The securities to be purchased at the closing are shares of common stock, par value $0.001 per share, of the Company (“Common Stock”). 

B. Exemption from Securities Registration. The Parties are executing and delivering this Agreement in reliance upon the exemption from
securities registration afforded by Section 4(a)(2) of the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the “Securities Act”) and the provisions of Regulation D or other
applicable exemptions from registration, as promulgated by the U.S. Securities and Exchange Commission under the Securities Act. 
 C.
Registration Rights Agreement. At the Closing, the Company and the Investor will enter into a Registration Rights Agreement, substantially in the form attached as Exhibit C hereto (the “Registration Rights Agreement”),
pursuant to which the Company has agreed to provide certain registration rights with respect to the Purchased Shares issued and sold to the Investor, under the Securities Act and applicable state securities laws. 

D. Warrant. As of the date hereof, the Company and the Investor have entered into a Warrant (the “Warrant”), pursuant
to which the Company has agreed to issue to the Investor a warrant with the right to purchase a number of shares of Common Stock subject to the terms and conditions as set forth therein. 

E. Transaction Documents. The term “Transaction Documents” refers to this Agreement, the Registration Rights Agreement
the Warrant and each of the other agreements and documents entered into or delivered by the parties hereto in connection with the transactions contemplated hereby or thereby. 

NOW, THEREFORE, in consideration of the premises, and of the representations, warranties, covenants and agreements set forth herein,
the parties agree as follows: 
 ARTICLE I 

PURCHASE; PURCHASE PRICE; AND CLOSINGS 

SECTION 1.1. Purchase. On the terms and subject to the conditions set forth herein, the Investor will purchase from the Company, and
the Company will issue and sell to the Investor, such number of shares of Common Stock equal to the quotient resulting from dividing the Aggregate Purchase Price by the Purchase Price Per Share, rounded down to the nearest whole share of Common
Stock (such shares of Common Stock collectively, the “Purchased Shares”). 

 SECTION 1.2. Purchase Price. The purchase price per Purchased Share (the “Purchase
Price Per Share”) shall be an amount equal to the lower of (i) the closing price of the shares of Common Stock, on and as reported on NASDAQ, on the date hereof and (ii) the VWAP of the shares of Common Stock, on and as reported
on NASDAQ, for the ten (10) Trading Days immediately prior to the date hereof (including the date hereof). The parties agree that the aggregate purchase price (the “Aggregate Purchase Price”) shall be US$50,000,000.
“VWAP” means, for any date, the price determined by the daily volume weighted average price of shares of the Common Stock for such date (or the nearest preceding date) on NASDAQ (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:00 p.m. (New York City time)). “Trading Day” means a day on which shares of the Common Stock are listed or quoted and traded on NASDAQ. 

SECTION 1.3. Closing. Subject to the satisfaction (or, where permissible, waiver) of the conditions to the closing set forth in SECTION
1.4, the closing shall take place remotely via the exchange of documents and signatures (the “Closing”), on a date to be mutually agreed between the parties hereto in writing, and in any event simultaneously with, and subject to,
the consummation of the Borrowing under the Credit Agreement (the date on which the Closing actually occurs, the “Closing Date”). At the Closing, the Investor shall (i) pay to the Company the Aggregate Purchase Price by wire
transfer of immediately available funds in United States dollars to a bank account designated by the Company, and (ii) deliver to the Company a copy of the Registration Rights Agreement duly executed by the Investor. At the Closing, the Company
shall (i) deliver to the Investor a true and complete copy of the duly passed resolutions of the board of directors of the Company (in the form of minutes or otherwise), or the relevant extracts thereof, evidencing approval of the execution,
delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a named party and the consummation of the transactions contemplated hereunder and thereunder and (ii) deliver to the Investor a copy of
the Registration Rights Agreement duly executed by the Company. On the Closing Date, the Company shall instruct the transfer agent for the Common Stock (the “Transfer Agent”) to promptly credit the Investor the Purchased Shares
(and, upon request of such Investor, shall instruct the Transfer Agent to deliver stock certificates to the Investor representing the Purchased Shares), 

SECTION 1.4. Closing Conditions. 

(a) The obligation of the Investor to consummate the Closing is subject to the fulfillment prior to or contemporaneously with the Closing of
each of the following conditions: 
 (i) no judgment, injunction, order, ruling, verdict, decree or other similar
determinations or finding (a “Governmental Order”) by, before or under the supervision of any court, administrative agency or commission or other governmental authority or instrumentality, whether federal, state, local or foreign,
or any applicable industry self-regulatory organization (each, a “Governmental Entity”) that would have the effect of prohibiting the Closing shall be in effect, and no lawsuit commenced by any Governmental Entity seeking to
prohibit the Closing shall be pending; 

  
 2 

 (ii) the representations and warranties of the Company set forth in SECTION 2.1
of this Agreement shall be true and correct in all material respects as of the date hereof and as of the Closing Date (except (A) to the extent such representations and warranties are made as of a specified date, in which case such
representations and warranties shall be true and correct in all material respects as of such date, and (B) any representations and warranties that have “material” or “Material Adverse Effect” qualifications, in which case
such representations and warranties shall be true in all respects); 
 (iii) the Company shall have performed in all material
respects all obligations required to be performed by it at or prior to or contemporaneously with the Closing under this Agreement; 

(iv) the Company shall have obtained all consents, permits, approvals, registrations and waivers necessary and appropriate for
the consummation of the transactions contemplated herein and in the other Transaction Documents, all of which shall be in full force and effect; 

(v) the Company shall have delivered to the Investor a duly executed (A) Officer’s Certificate in the form set forth
in Exhibit A hereto and (B) Secretary’s Certificate certifying (1) the Company’s board resolutions approving this Agreement and the other Transaction Documents and the issuance of the Purchased Shares, and (2) the
Company’s Certificate of Incorporation and Bylaws, each as amended through the date hereof; and 
 (vi) the transactions
under the Credit Agreement and Guaranty (the “Credit Agreement”), pursuant to which the Lenders (as defined in the Credit Agreement) shall provide to the Company a senior secured term loan facility in an aggregate principal amount
of US$50,000,000, shall have been consummated in accordance with the terms and conditions thereof; 
 (vii) the Investor
shall have received an opinion from Simpson Thacher and Bartlett LLP substantially in the form set forth in Exhibit B hereto (with changes, if any, as may be agreed by Investor acting reasonably and in good faith); and 

(viii) no stop order or suspension of trading shall have been imposed or threatened in writing by any Governmental Authority or
self-regulatory organization with respect to public trading in the Company’s stock. 
 (b) The obligation of the Company to consummate
the Closing is subject to the fulfillment prior to the Closing of each of the following conditions: 
 (i) no Governmental
Order by, before or under a Governmental Entity that would have the effect of prohibiting the Closing shall be in effect, and no lawsuit commenced by any Governmental Entity seeking to prohibit the Closing shall be pending; 

  
 3 

 (ii) the representations and warranties of the Investor set forth in SECTION 2.2
of this Agreement shall be true and correct in all material respects as of the date hereof and as of the Closing Date (except to the extent such representations and warranties are made as of a specified date, in which case such representations and
warranties shall be true and correct in all material respects as of such date); and 
 (iii) the Investor shall have
performed in all material respects all obligations required to be performed by it at or prior to or contemporaneously with the Closing under this Agreement. 

ARTICLE II 

REPRESENTATIONS AND WARRANTIES 

SECTION 2.1. Representations and Warranties of the Company. The Company represents and warrants to the Investor as of the date hereof
and as of the Closing Date (except to the extent made only as of a specified date, in which case as of such date) that, except as set forth in the reports, registrations, documents, filings, statements, schedules and submissions together with any
required amendments thereto filed with the U.S. Securities and Exchange Commission (the “SEC”) prior to the date of this Agreement (the “SEC Documents”): 

(a) Organization and Good Standing. The Company and each other Group Company have been duly organized and are validly existing and in
good standing (or the jurisdictional equivalent) under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing (or the jurisdictional equivalent) in each jurisdiction in which their
respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they
are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

(b) Due Authorization. The Company has full right, power and authority to execute and deliver the Transaction Documents and to perform
its obligations thereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of the Transaction Documents and the consummation by it of the transactions contemplated thereby has been duly and
validly taken. The Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally and to general equitable principles. 

(c) Capitalization. As of the date of this Agreement, (a) the authorized share capital of the Company is US$275,000,000, and
consists of 250,000,000 shares of Common Stock, of which 63,543,559 shares of Common Stock are outstanding, and 25,000,000 shares of preferred stock, of which none is outstanding, (b) all the outstanding shares of capital stock of the Company
have been duly and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights; (c) there are no
outstanding rights (including pre-

  
 4 

 
emptive rights), warrants, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interests in the Company or any of its subsidiaries, or any contract,
commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; and
(d) all of the outstanding shares of capital stock or other equity interests of each material subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party
(“Encumbrances”). The issuance and sale of the Purchased Shares hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Investors) and will not result in the
adjustment of the exercise, conversion, exchange or reset price of any outstanding security. 
 (d) Valid Issuance. The Purchased
Shares to be issued and sold by the Company hereunder have been duly authorized and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and
non-assessable, and shall be free and clear of Encumbrances (other than those created by the Investor), except for restrictions on transfer imposed by applicable securities laws. 

(e) No Violation or Default. Neither the Company nor any other Group Company is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any
term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any other Group Company is a party or by which the Company or any other Group Company is bound
or to which any property or asset of the Company or any other Group Company is subject; or (iii) in violation of any law or statute, including laws of foreign jurisdictions, tax laws, environmental protection laws, health and pharmaceutical
regulatory laws, social security laws or labor laws, or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii) and (iii) above, for any such default or
violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 (f) No
Conflicts. The execution, delivery and performance by the Company of the Transaction Documents, the issuance and sale of the Purchased Shares and the consummation of the transactions contemplated by the Transaction Documents will not
(i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or
encumbrance upon any property, right or asset of the Company or any other Group Company pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any other Group Company is a party
or by which the Company or any other Group Company is bound or to which any property, right or asset of the Company or any other Group Company is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any other Group Company or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator
or governmental or regulatory authority, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation or default that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. 

  
 5 

 (g) No Consents Required. Assuming the accuracy of the representations and warranties of
the Investor set forth in SECTION 2.2, no consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required to be made or obtained by the Company for the
execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Purchased Shares and the consummation of the transactions contemplated by the Transaction Documents, except for those that have been made or obtained
prior to the date hereof, post-Closing filings pursuant to securities laws and the rules and regulation of The NASDAQ Stock Market LLC, which the Company shall file within the applicable time periods and the registration of the Purchased Shares
under the Securities Act as and when required under the Registration Rights Agreement. 
 (h) Financial Statements. As of their
respective dates, the financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2017, as filed with the SEC on March 26, 2018 comply in all material respects with the applicable requirements of the Securities Act and present fairly the financial position of the Company and its consolidated subsidiaries as
of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in all material aspects in conformity with generally accepted accounting
principles (“GAAP”) in the United States applied on a consistent basis throughout the periods covered thereby, and any supporting schedules included in the SEC Documents present fairly in all material aspects the information
required to be stated therein; and the other financial information included in the SEC Documents has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material aspects the
information shown thereby. 
 (i) Regulatory Filings. Except as would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect, neither the Company nor any other Group Company has failed to file with the regulatory authorities any required filing, declaration, listing, registration, report or submission with respect to the product candidates
of the Company or the other Group Companies that are described or referred to in the SEC Documents; all such filings, declarations, listings, registrations, reports or submissions were in material compliance with Applicable Laws when filed; and no
material deficiencies regarding compliance with Applicable Law have been asserted by any applicable regulatory authority with respect to any such filings, declarations, listings, registrations, reports or submissions. 

(j) Title to Real and Personal Property. The Company and the other Group Companies have good and marketable title in fee simple to, or
have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and the other Group Companies, in each case free and clear of all Liens, except those that (i) do
not materially interfere with the use made and proposed to be made of such property by the Company and the other Group Companies or (ii) would not, individually or in the aggregate, reasonably be excepted to have a Material Adverse Effect. 

  
 6 

 (k) Tax. The Company and the other Group Companies have paid all federal, state, local and
foreign taxes and filed all tax returns required to be paid or filed through the date hereof except where such failure to pay or file would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except
as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any other Group Company or any
of their respective properties or assets. To the Company’s knowledge, no tax investigation is currently pending against the Company or any other Group Company. The provisions included in the financial statements as set out in the SEC Documents
included appropriate provisions required under U.S. GAAP for all taxation in respect of accounting periods ended on or before the accounting reference date to which such audited accounts relate for which the Company was then or might reasonably be
expected thereafter to become or have become liable. 
 (l) Absence of Certain Changes. Since the date of the most recent financial
statements of the Company included in the SEC Documents, (i) there has not been any change in the capital stock (other than the issuance of Common Stock upon exercise of any stock options and warrants described as outstanding in, and the grant
of any options and awards under existing equity incentive plans described in, the SEC Documents), short-term debt or long-term debt of the Company or any other Group Company, or any dividend or distribution of any kind declared, set aside for
payment, paid or made by the Company on any class of capital stock, or any other change or development that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, (ii) neither the Company
nor any other Group Company has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and the other Group Companies taken as a whole or incurred any liability or obligation,
direct or contingent, that is material to the Company and the other Group Companies taken as a whole (other as described in the SEC Documents); (iii) there has not been any material damage, destruction or loss, whether or not covered by insurance to
any assets or properties of the Company or any Group Company, that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, (iv) there has not been any material labor difficulties or labor
union organizing activities with respect to employees of the Company or any Group Company that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, and (v) there has not been any other
event or condition of any character that has had or could be reasonably expected to have a Material Adverse Effect. 
 (m) Legal
Proceedings. As of the date of this Agreement, (i) there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (“Actions”) pending to which the
Company, any other Group Company or any directors, director nominees or executive officers (in their respective capacities as such) of any Group Company is a party or to which any property of the Company or any other Group Company is the subject
that, individually or in the aggregate, if determined adversely to the Company or any other Group Company, would reasonably be expected to have a Material Adverse Effect; (ii) no such Actions are, to the knowledge of the Company, threatened;
(iii) there are no prior, current or pending Actions that are required under the Securities Act to be described in the SEC Documents that are not so described in the SEC Documents, and (iv) there are no statutes, regulations or contracts
or other documents that are required under the Securities Act to be filed as exhibits to the SEC Documents or described in the SEC Documents that are not so filed as exhibits to the SEC Documents or described in the SEC Documents. 

  
 7 

 (n) Material Contracts. Each franchise, contract or other document of a character required
to be described in the SEC Documents or to be filed as an exhibit to the SEC Documents under the Securities Act and the rules and regulations promulgated thereunder is so described or filed. All such agreements and contracts are valid, binding, in
full force and effect and enforceable against each of the parties thereto. Neither the Company, nor, to the Company’s knowledge, any other party thereto, is in material default of any of its obligations under any such agreement or contract.

 (o) Licenses and Permits. The Company and the other Group Companies possess, and are in material compliance with the terms of, all
material licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the
ownership or lease of their properties or the conduct of their business as described in the SEC Documents, except where the failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect; and neither the Company nor any other Group Company has received notice of any revocation or modification of any such material license, certificate, permit or authorization or has any reason to believe that any such material license,
certificate, permit or authorization will not be renewed in the ordinary course except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and the other Group Companies (i) are,
and at all times since January 1, 2017 have been, in compliance with all statutes, rules and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or
disposal of any product manufactured or distributed by the Company (“Applicable Laws”); and (ii) have not received any U.S. Food and Drug Administration Form 483, written notice of adverse finding, warning letter, untitled
letter or other correspondence or written notice from any court or arbitrator or governmental or regulatory authority alleging or asserting non-compliance with (x) any Applicable Laws or (y) any
licenses, exemptions, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws except in each case of clause (i) and clause (ii), as would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect. Without limiting the generality of the foregoing, all preclinical and clinical studies conducted by or, to the Company’s knowledge, on behalf of the Company to support
approval for commercialization of the Company’s products have been conducted by the Company, or to the Company’s knowledge by third parties, in compliance with all applicable federal, state or foreign laws, rules, orders and regulations,
except for such failure or failures to be in compliance which could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. The descriptions of the tests and preclinical and clinical studies, and results
thereof, conducted by or, to the Company’s knowledge, on behalf of the Company contained in the SEC Documents are accurate and complete in all material respects; and the Company has not received any oral or written notice or correspondence from
the FDA or any foreign, state or local governmental body exercising comparable authority requiring the termination, suspension, or clinical hold of any tests or preclinical or clinical studies, or such written notice or correspondence from any
Institutional Review Board or comparable authority requiring the termination or suspension of a clinical study, conducted by or on behalf of the Company, which termination, suspension, or clinical hold would reasonably be expected to have a Material
Adverse Effect. 

  
 8 

 (p) Compliance with Anti-Money Laundering Laws. The operations of the Company and the
other Group Companies are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Organised and Serious Crimes Ordinance (Chapter 455 of the Laws of Hong Kong),
the Anti-Money Laundering and Counter-Terrorist Financing (Financial Institutions) Ordinance (Chapter 615 of the Laws of Hong Kong), the Drug Trafficking (Recovery of Proceeds) Ordinance (Chapter 405 of the Laws of Hong Kong), the United Nations
(Anti-Terrorism Measures) Ordinance (Chapter 575 of the Laws of Hong Kong), the applicable anti-money laundering statutes of all jurisdictions where the Company or any other Group Company conducts business, the applicable rules and regulations
thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental or regulatory agency (collectively, the “Anti-Money Laundering Laws”) and no action, suit or proceeding by
or before any court or governmental or regulatory agency, authority or body or any arbitrator involving the Company or any other Group Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 (q) No Conflicts with Sanctions Laws. Neither the Company nor any other Group Company or any directors, officers or employees (in
their respective capacity as such) of any Group Company, nor, to the knowledge of the Company, any agent acting on behalf of the Company or any other Group Company is currently the subject or the target of any sanctions administered or enforced by
the U.S. government, (including the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including the designation as a “specially designated national” or “blocked person”),
the United Nations Security Council, the European Union, Her Majesty’s Treasury or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company or any other Group Company located, organized or resident in
a country or territory that is the subject or target of Sanctions (each, a “Sanctioned Country”); and the Company will not directly or indirectly use the proceeds of the sale of the Purchased Shares hereunder, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject
or target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction,
whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and the other Group Companies have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person
that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. 
 (r) No
Labor Disputes. 
 (i) The Company is not a party to or bound by any collective bargaining agreements or other agreements
with labor organizations. The Company has not violated any laws, regulations, orders or contract terms, affecting the collective bargaining rights of employees, labor organizations or any laws, regulations or orders affecting employment
discrimination, equal opportunity employment, or employees’ health, safety, welfare, wages and hours, which violation, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect. 

  
 9 

 (ii) (A) There are no labor disputes existing, or to the Company’s
knowledge, threatened, involving strikes, slow-downs, work stoppages, job actions, disputes, lockouts or any other disruptions of or by the Company’s employees that, individually or in the aggregate, has had or would reasonably be expected to
have a Material Adverse Effect, (B) there are no unfair labor practices or petitions for election pending or, to the Company’s knowledge, threatened before the National Labor Relations Board or any other federal, state, foreign or local
labor commission relating to the Company’s employees that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, and (C) no demand for recognition or certification heretofore made by
any labor organization or group of employees is pending with respect to the Company. 
 (iii) The Company is, and at all
times has been, in compliance with all applicable laws respecting employment (including laws relating to classification of employees and independent contractors) and employment practices, terms and conditions of employment, wages and hours, and
immigration and naturalization, except for such failure or failures to be in compliance which could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. There are no material claims pending, or to the
Company’s knowledge threatened, against the Company before the Equal Employment Opportunity Commission or any other administrative body or in any court asserting any violation of Title VII of the Civil Rights Act of 1964, the Age Discrimination
Act of 1967, 42 U.S.C. §§ 1981 or 1983 or any other federal, state, foreign or local Law, statute or ordinance barring discrimination in employment. 

(s) Investment Company Act. The Company is not and, after giving effect to the issuance and sale of the Purchased Shares and the
application of the proceeds thereof, will not be, required to register as an “investment company” or an entity “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940, as
amended, and the rules and regulations of the Commission thereunder. 
 (t) No Unlawful Payments. Neither the Company nor any other
Group Company nor any director, officer, or employee (in their respective capacity as such) of the Company or any other Group Company nor, to the knowledge of the Company, any agent, acting on behalf of the Company or any Group Company has
(i) used any funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an intentional act in furtherance of an offer, promise or authorization of any direct or
indirect unlawful payment or benefit to any government or regulatory official or employee, including any directors, officers and employees of any wholly or partially government-owned or controlled entity or of a public international organization, or
any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices

  
 10 

 
Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed
an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption laws; or (iv) made, offered, promised, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful
benefit, including any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and the Group Companies have instituted, and maintain and enforce, policies and procedures designed to promote and
reasonably ensure compliance with all applicable anti-bribery and anti-corruption laws. 
 (u) Certain Environmental Matters. The
Company and the other Group Companies are currently in compliance with all, and have not since January 1, 2017 violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions,
judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants
(collectively, “Environmental Laws”), except in the case that such failure to comply would not individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

(v) Accounting Controls. The Company and the other Group Companies maintain systems of “internal control over financial
reporting” (as defined in Rule 13a-15(f) of the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”)) that comply
with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company and the other Group Companies maintain internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to any differences. There are no material weaknesses in the Company’s internal controls. The Company’s auditors and the Audit Committee of the board of directors
of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect
the Company’s ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal
controls over financial reporting. 
 (w) Intellectual Property. (i) The Company or another Group Company owns or has the right
to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names and other source indicators, copyrights and copyrightable works (including software), know-how, trade secrets, inventions, other unpatented and/or unpatentable systems, procedures, methods, processes, proprietary or 

  
 11 

 
confidential information and all other worldwide intellectual property, industrial property and proprietary rights (collectively, “Intellectual Property”) material to the conduct
of their respective businesses; (ii) the Company’s and the other Group Companies’ conduct of their respective businesses does not infringe, misappropriate or otherwise violate (“Infringe”) any Intellectual Property of
any person in any material respect (other than patents), nor, to the knowledge of the Company, does the Company Infringe patents of any person, and no Action is pending, or to the knowledge of the Company, threatened in writing, alleging
Infringement of Intellectual Property of any person; (iii) to the knowledge of the Company, the Intellectual Property owned by and exclusively licensed to the Company and the Group Companies is not being infringed, misappropriated or otherwise
violated by any person in any material respect; (iv) no Action is pending, or to the knowledge of the Company, threatened in writing, challenging the validity, enforceability, scope, registration, ownership or use of any Intellectual Property
owned by or exclusively licensed to the Company or any other Group Company (with the exception of ordinary course office actions in connection with applications for the registration or issuance of such Intellectual Property); and (v) the
Company and the Group Companies take reasonable measures to maintain and protect their material Intellectual Property. All of the material licenses and sublicenses and consent, royalty or other agreements concerning Intellectual Property which are
necessary for the conduct of the Company’s and/or each of its Group Company respective businesses as currently conducted to which the Company or any Group Company is a party or by which any of their assets are bound (other than generally
commercially available, non-custom, off-the-shelf software application programs having a retail acquisition price of less than
$200,000 per license, and other than non-exclusive licenses granted in the ordinary course of business) (collectively, “License Agreements”) are valid and binding obligations of the Company or
any of its Group Companies that are parties thereto and, to the Company’s knowledge, the other parties thereto, enforceable in accordance with their terms, except to the extent that enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally. Neither the Company, nor, to the Company’s knowledge, any other party thereto, is in material default of any
of its obligations under any such License Agreement. 
 (x) No “Bad Actor” Disqualification. No “bad actor”
disqualifying event described in Rule 506(d)(1)(i)-(viii) promulgated by the SEC (a “Disqualification Event”) is applicable to the Company or, to the Company’s knowledge, any Company Covered Person (as defined below).
“Company Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated by the SEC under the Act, any person or entity listed in the first paragraph of Rule 506(d)(1). 

(y) Compliance with Listing Requirements. The Common Stock is registered pursuant to Section 12(b) of the 1934 Act and is listed on
The NASDAQ Capital Markets, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the 1934 Act or removal from listing of the Common Stock from the NASDAQ Capital
Markets, nor has the Company received any notification that the SEC, the NASDAQ Stock Market or the Financial Industry Regulatory Authority, Inc. is contemplating terminating such registration or quotation. The Company is in compliance in all
material respects with the listing and listing maintenance requirements of the NASDAQ Capital Markets applicable to it for the continued trading of its Common Stock on the NASDAQ Capital Markets. 

  
 12 

 (z) No Broker’s Fees. Neither the Company nor any other Group Company is a party to
any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them for a brokerage commission, finder’s fee or like payment in connection with the issuance and sale of
the Purchased Shares. 
 (aa) Disclosures. As of their respective filing or furnishing dates, the SEC Documents complied in all
material respects with the requirements of the Securities Act and/or the Exchange Act, as the case may be, and the rules and regulations of the SEC promulgated thereunder, as applicable, to the respective SEC Documents. None of the SEC Documents, at
the time they were filed or furnished, nor any of the representations and warranties set forth in this Section 2.1, as qualified thereby, contained or contain (as applicable) any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the statements therein or herein, in the light of the circumstances under which they were made, not misleading. 

SECTION 2.2. Representations and Warranties of the Investor. The Investor hereby represents and warrants as of the date hereof and as
of the Closing Date to the Company that: 
 (a) Organization and Good Standing. The Investor been duly organized and is validly
existing and in good standing (or the jurisdictional equivalent) under the laws of its jurisdiction of formation, and has all power and authority necessary to own or hold its properties and to conduct the businesses in which it is engaged, except
where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

(b) Due Authorization. The Investor has full right, power and authority to execute and deliver the Transaction Documents and to perform
its obligations thereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of the Transaction Documents and the consummation by it of the transactions contemplated thereby has been duly and
validly taken. The Transaction Documents constitute the legal, valid and binding obligations of the Investor, enforceable against the Investor in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally and to general equitable principles. 

(c) No Conflicts. The execution, delivery and performance by the Investor of the Transaction Documents, the purchase of the Purchased
Shares and the consummation of the transactions contemplated by the Transaction Documents will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the
termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Investor pursuant to, any indenture, mortgage, deed of trust, loan agreement or other
agreement or instrument to which the Investor is a party or by which the Investor is bound or to which any property, right or asset of the Investor is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Investor or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or
regulatory 

  
 13 

 
authority, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation or default that would not, individually or in the aggregate, reasonably be expected to
have a material adverse effect on the Investor to consummate the transactions contemplated by, and perform its obligations under, the Transaction Documents. 

(d) No Consents Required. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator
or governmental or regulatory authority is required by the Investor for the execution, delivery and performance by the Investor of this Agreement, the purchase of the Purchased Shares and the consummation of the transactions contemplated by the
Transaction Documents, except for the registration of the Purchased Shares under the Securities Act as and when required under the Registration Rights Agreement. 

(e) Purchase for Investment. The Investor acknowledges that the Purchased Shares are “restricted securities” and have not been
registered under the Securities Act or under any state securities laws. The Investor (1) is acquiring the Purchased Shares pursuant to an exemption from registration under the Securities Act for its own account solely for investment with no
present intention or plan to distribute any of the Purchased Shares to any person nor with a view to or for sale in connection with any distribution thereof, in each case in violation of the Securities Act, (2) will not sell or otherwise
dispose of any of the Purchased Shares, except in compliance with the registration requirements or exemption provisions of the Securities Act and any other applicable securities laws, (3) is an “accredited investor” (as that term is
defined by Rule 501 of the Securities Act) and (4) is not a registered broker-dealer registered under Section 15(a) of the Exchange Act, or a member of FINRA or an entity engaged in the business of being a broker-dealer. Such Investor is
not affiliated with any broker-dealer registered under Section 15(a) of the Exchange Act, or a member of FINRA or an entity engaged in the business of being a broker-dealer. Without limiting any of the foregoing, neither the Investor nor any of
its Affiliates has taken, and the Investor will not, and will cause its Affiliates not to, take any action that would otherwise cause the securities to be purchased hereunder to be subject to the registration requirements of the Securities Act. 

(f) Financial Capability. The Investor has and will have at Closing immediately available funds necessary to consummate the Closing on
the terms and conditions contemplated by this Agreement. 
 (g) Sophisticated Investor. The Investor is knowledgeable, sophisticated
and experienced in making, and is qualified to make, decisions with respect to investments in shares representing an investment decision like that involved in the purchase of the Purchased Shares, including investments in securities issued by the
Company, and has requested, received, reviewed and considered all information it deems relevant in making an informed decision to evaluate the merits and risks of a purchase of the Purchased Shares, and can bear the economic risk and complete loss
of its investment in the Purchased Shares. 
 (h) Existing Ownership. The Investor does not legally or Beneficially Own or control,
directly or indirectly, any shares, convertible debt or any securities convertible into or exercisable or exchangeable for, or any rights, warrants or options to acquire, any shares or convertible debt in the Company, or have any agreement,
understanding or arrangement to acquire any of the foregoing, except with respect to such Purchased Shares as to be purchased by the Investor pursuant to the transactions contemplated herein. 

  
 14 

 (i) No General Solicitation. The Investor did not learn of the investment in the Purchased
Shares as a result of any general solicitation or general advertising. 
 (j) Reliance on Exemptions. The Investor understands that
the Purchased Shares offered and sold to it in reliance on specific exemptions from the registration requirements of U.S. federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and the
Investor’s compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility of the Investor to
acquire the Purchased Shares. 
 (k) No Broker’s Fees. The Investor is not a party to any contract, agreement or understanding
with any person (other than this Agreement) that would give rise to a valid claim against any of them for a brokerage commission, finder’s fee or like payment in connection with the purchase of the Purchased Shares. 

ARTICLE III 
 COVENANTS

 SECTION 3.1. Filings; Other Actions. 

(a) Each of the Investor and the Company will use its commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or
cause to be done all things necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement, including using commercially reasonable efforts to accomplish
the following: (a) all acts reasonably necessary to cause the conditions to Closing to be satisfied; (b) the obtaining of all necessary actions or no actions, waivers, consents and approvals from Governmental Entities and the making of all
necessary registrations and filings and the taking of all reasonable steps necessary to obtain an approval or waiver from, or to avoid an action or proceeding by any Governmental Entity; (c) the obtaining of all necessary consents, approvals or
waivers from third parties; and (d) executing and delivering any additional instruments necessary to consummate the transactions contemplated by, and to fully carry out the purposes of, this Agreement. In furtherance of the foregoing, the
Investor and the Company will cooperate and consult with each other and use commercially reasonable efforts to prepare and file all necessary documentation, to effect all necessary applications, notices, petitions, filings, and other documents, and
to obtain all necessary permits, consents, orders, approvals, and authorizations of, or any exemption by, all third parties and Governmental Entities, and expiration or termination of any applicable waiting periods, necessary or advisable to
consummate the transactions contemplated by this Agreement and to perform covenants contemplated by this Agreement. Each party shall execute and deliver both before and after the Closing such further certificates, agreements, and other documents and
take such other actions as the other party may reasonably request to consummate or implement such transactions or to evidence such events or matters. 

  
 15 

 (b) Each party agrees, upon reasonable request, to furnish the other party with all information
concerning itself, its subsidiaries, Affiliates, directors, officers, partners, and shareholders and such other matters as may be reasonably necessary or advisable in connection with any statement, filing, notice, or application made by or on behalf
of such other party or any of its subsidiaries to any Governmental Entity in connection with this Agreement. Notwithstanding anything herein to the contrary, neither the Investor nor the Company shall be required to furnish the other party with any
(1) sensitive personal biographical or personal financial information of any of the directors, officers, employees, managers or partners of the Investor or any of its Affiliates, (2) proprietary and
non-public information related to the organizational terms of, or investors in, the it or its Affiliates, or (3) any information that it deems private or confidential. 

SECTION 3.2. Expenses. Each of the parties will bear and pay all costs and expenses incurred by it or on its behalf in connection with
this Agreement and the transactions contemplated under this Agreement; provided that the Company shall reimburse Investor for the reasonable and documented fees of its counsel, up to a maximum of $15,000. 

SECTION 3.3. Confidentiality. Each party to this Agreement will hold, and will cause its respective subsidiaries and their directors,
officers, employees, agents, consultants, and advisors to hold, in strict confidence, unless disclosure to a Governmental Entity is necessary in connection with any necessary regulatory approval or unless compelled to disclose by judicial or
administrative process or, in the written opinion of its counsel, by other requirement of law or the applicable requirements of any Governmental Entity, all nonpublic records, books, contracts, instruments, computer data and other data and
information (collectively, “Information”) concerning the other party hereto furnished to it by such other party or its representatives pursuant to this Agreement (except to the extent that such information can be shown to have been
(1) previously known by such party on a nonconfidential basis, (2) in the public domain through no fault of such party, or (3) later lawfully acquired from other sources by the party to which it was furnished), and neither party
hereto shall release or disclose such Information to any other person, except its auditors, attorneys, financial advisors, other consultants, and advisors. If a party is required to disclose any Information to a Governmental Entity in accordance
with this SECTION 3.3, the disclosing party shall notify the other party prior to making any such disclosure by providing the other party with the text of the disclosure requirement and draft disclosure at least 24 hours prior to making any such
disclosure, and will narrow the draft disclosure to the extent the other party reasonably requests. 
 SECTION 3.4. Representations and
Warranties. 
 (a) Prior to the Closing, the Company shall promptly provide the Investor with written notice of the occurrence of any
circumstance, event, change, development or effect occurring after the date hereof and relating to the Company or any Group Company of which the Company has knowledge or, in the reasonable judgment of the Company, may otherwise cause or render any
of the representations and warranties of the Company set forth in SECTION 2.1 of this Agreement to be inaccurate in any material respect. 

(b) Prior to the Closing, the Investor shall promptly provide the Company with written notice of the occurrence of any circumstance, event,
change, development or effect occurring after the date hereof and relating to the Investor of which the Investor has knowledge or, in the reasonable judgment of the Investor, may otherwise cause or render any of the representations and warranties of
the Investor set forth in SECTION 2.2 of this Agreement to be inaccurate in any material respect. 

  
 16 

 SECTION 3.5. Registration Statements. The Company shall not, and shall use its
commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that will be integrated
with the offer or sale of the Purchased Shares in a manner that would require the registration under the 1933 Act of the sale of the Purchased Shares to the Investor, or that will be integrated with the offer or sale of the Purchased Shares for
purposes of the rules and regulations of any trading market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.

 ARTICLE IV 

ADDITIONAL AGREEMENTS 

SECTION 4.1. Compliance with Laws. 

(a) The Investor acknowledges that it is aware of, and that will advise its representatives of, the restrictions imposed by applicable United
States and other applicable jurisdictions’ securities laws with respect to trading in securities while in possession of material non-public information relating to the issuer of such securities and on
communication of such information when it is reasonably foreseeable that the recipient of such information is likely to trade such securities in reliance on such information. 

SECTION 4.2. Legend. 
 (a)
The Investor agrees that all certificates or other instruments representing the securities subject to this Agreement will bear a legend substantially to the following effect: 

“THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR THE
SECURITIES LAWS OF ANY STATE AND MAY NOT BE TRANSFERRED, SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT WHILE A REGISTRATION STATEMENT RELATING THERETO IS IN EFFECT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS
OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS. ANY ATTEMPT TO TRANSFER, SELL, OFFER TO SELL, PLEDGE, HYPOTHECATE OR OTHERWISE DISPOSE OF THIS INSTRUMENT IN VIOLATION OF THESE RESTRICTIONS SHALL BE VOID.” 

  
 17 

 (b) Upon request of the Investor, upon receipt by the Company of an opinion of counsel and other
customary representations and other documentation from the Investor, in each case, reasonably satisfactory to the Company, to the effect that such legend is no longer required under the Securities Act or applicable state laws, as the case may be,
the Company shall promptly cause the legend to be removed from any certificate for any securities. The Investor acknowledges that the Purchased Shares have not been registered under the Securities Act or under any state securities laws and agrees
that it will not sell or otherwise dispose of any of the Purchased Shares except in compliance with the registration requirements or exemption provisions of the Securities Act and any other applicable securities laws. 

SECTION 4.3. Indemnity. 

(a) The Company shall indemnify Investor and its Affiliates (collectively, the “Investor Indemnified Parties”) and hold each
of them harmless against any actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith, and including reasonable attorneys’ fees and disbursements (the
“Losses”) suffered, incurred or paid by the Investor Indemnified Parties arising from: (i) any breach of any representation or warranty made by the Company in SECTION 2.1 to be true and correct as of the date hereof and as of
the Closing Date; or (ii) any breach of any covenant or agreement by the Company contained in this Agreement. Other than with respect to fraud, in no event shall the Company be liable for or have an obligation to indemnify or hold harmless the
Investor Indemnified Parties for Losses (i) in connection with the representations and warranties in SECTION 2.1(a), SECTION 2.1(b) and SECTION 2.1(d) (collectively, the “Fundamental Representations”) in excess of the Aggregate
Purchase Price paid to the Company pursuant to this Agreement and (ii) in connection with the representations and warranties other than the Fundamental Reps in excess of US$15,000,000, and the Company shall not be liable to the Investor
Indemnified Parties for any Losses unless the aggregate amount of all Losses incurred by the Investor Indemnified Parties exceeds US$750,000 in the aggregate (the “Basket”), in which case the Company shall be liable for all such
Losses in excess of the Basket. The Company shall not be liable to the Investor Indemnified Parties for any Losses arising under this SECTION 4.3 relating to an individual claim resulting in Losses in the amount of US$100,000 or less (a “De
Minimis Claim”), regardless of whether or not aggregate Losses have exceeded the Basket; nor shall the amount of any such De Minimis Claims be taken into account in determining whether the Basket has been reached. Notwithstanding anything
to the contrary, in no event shall the aggregate liability of the Company to the Investor Indemnified Parties for any Losses in connection with the Transaction Documents and the transactions contemplated thereby exceed the Aggregate Purchase Price.

 (b) The Investor shall indemnify each of the Company and its Affiliates and each of their respective directors, officers, employees and
shareholders, owners (collectively, the “Company Indemnified Parties”) and hold each of them harmless against any and all Losses suffered, incurred or paid by the Company Indemnified Parties, arising from, as a result of or in
connection with any failure of any representation or warranty made by the Investor in SECTION 2.2(e) and/or SECTION 2.2(j) to be true and correct as of the date hereof and as of the Closing Date. 

(c) A party entitled to indemnification hereunder (an “Indemnified Party”) shall give written notice to the indemnifying party
(the “Indemnifying Party”) of any claim with respect to which it seeks indemnification promptly after the discovery by such Indemnified Party of any matters giving rise to a claim for indemnification; provided that the
failure of any 

  
 18 

 
Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this SECTION 4.3 unless and to the extent that the Indemnifying Party shall
have been actually materially prejudiced by the failure of such Indemnified Party to so notify such party. No claim for indemnification may be asserted against any Indemnifying Party for breach of any representation, warranty, covenant or agreement
contained herein unless written notice of such claim is received by such Indemnifying Party on or prior to the date on which the representation, warranty, covenant or agreement on which such claim or proceeding is based ceases to survive as set
forth in SECTION 6.1. Such notice shall describe in reasonable detail such claim. In case any such action, suit, claim or proceeding is brought against an Indemnified Party, the Indemnified Party shall be entitled to hire, at the cost and expense of
the Indemnifying Party, counsel and conduct the defense thereof; provided, however, that the Indemnifying Party shall only be liable for the legal fees and expenses of one law firm for the Indemnified Parties, taken together with
regard to any single action or group of related actions, upon agreement by the Indemnified Parties and the Indemnifying Party. If the Indemnifying Party assumes the defense of any claim, the Indemnified Parties shall thereafter deliver to the
Indemnifying Party copies of all notices and documents (including court papers) received by the Indemnified Parties relating to the claim, and the Indemnified Parties shall cooperate in the defense or prosecution of such claim. Such cooperation
shall include the retention and (upon the Indemnifying Party’s request) the provision to the Indemnifying Party of records and information that are reasonably relevant to such claim, and making employees available on a mutually convenient basis
to provide additional information and explanation of any material provided hereunder. The Indemnifying Party shall not be liable for any settlement of any action, suit, claim or proceeding effected without its written consent; provided,
however, that the Indemnifying Party shall not unreasonably withhold, delay or condition its consent. The Indemnifying Party further agrees that it will not, without any Indemnified Party’s prior written consent (which shall not be
unreasonably withheld or delayed), settle or compromise any claim or consent to entry of any judgment in respect thereof in any pending or threatened action, suit, claim or proceeding in respect of which indemnification has been sought hereunder
unless such settlement or compromise includes an unconditional release of such Indemnified Party from all liability arising out of such action, suit, claim or proceeding. 

(d) In calculating the amount of any Losses hereunder, there shall be subtracted the amount of any insurance proceeds and third-party payments
received by the Indemnified Parties with respect to such Losses, if any, net of any actual costs or expenses incurred in connection with securing or obtaining such proceeds or payments. In no event shall any Indemnified Party be entitled to recover
or make a claim for any amounts in respect of, and in no event shall “Losses” be deemed to include, consequential or indirect damages, lost profits or punitive damages and, in particular, no “diminution of value”, “multiple
of profits” or “multiple of cash flow” or similar valuation methodology shall be used in calculating the amount of any Losses, unless in any such case, such Losses are awarded to a third party. 

(e) Absent a showing of fraud by a party, and assuming the Closing has occurred, the indemnification obligation of a party under this SECTION
4.3 shall be the sole and exclusive remedy of any other party against such party for monetary damages for breach of any representation, warranty, covenant or agreement contained in this Agreement or any of the transactions contemplated hereby.
Nothing herein shall limit a party’s right to seek injunctive or other equitable relief in connection with the enforcement of this Agreement. 

  
 19 

 (f) Any indemnification payments pursuant to this SECTION 4.3 shall be treated as an adjustment
to the investment amount for the Purchased Shares for U.S. federal income and applicable state and local tax purposes, unless a different treatment is required by applicable law. 

SECTION 4.4. Registration Rights. At the Closing, the Company, the Investor and the other parties thereto will each enter into the
Registration Rights Agreement, substantially in the form attached as Exhibit C hereto. 
 ARTICLE V 

TERMINATION 
 SECTION 5.1.
Termination. This Agreement may be terminated prior to the Closing: 
 (a) by mutual written consent of the Investor and the Company;

 (b) by the Company, upon written notice to the Investor, in the event that any of the conditions of Closing set forth in SECTION 1.4(b)
are not satisfied, or waived by the Company, on or before the 30th day after the date hereof; provided, however, that the right to terminate this Agreement pursuant to this SECTION 5.1(b)
shall not be available to any party whose failure to fulfill any obligation under this Agreement shall have been the cause of, or shall have resulted in, the failure of the Closing to occur on or prior to such date; 

(c) by the Investor, upon written notice to the Company, in the event that the conditions of Closing set forth in SECTION 1.4(a) are not
satisfied, or waived by the Investor, on or before the 30th day after the date hereof; provided, however, that the right to terminate this Agreement pursuant to this SECTION 5.1(c) shall not be
available to any party whose failure to fulfill any obligation under this Agreement shall have been the cause of, or shall have resulted in, the failure of the Closing to occur on or prior to such date; or 

(d) by the Company, upon written notice to the Investor, in the event that any Governmental Entity shall have issued any order, decree or
injunction or taken any other action restraining, enjoining or prohibiting any of the transactions contemplated by this Agreement, and such order, decree, injunction or other action shall have become final and nonappealable. 

SECTION 5.2. Effects of Termination. In the event of any termination of this Agreement as provided in SECTION 5.1, this Agreement
(other than SECTION 3.2, SECTION 3.3, SECTION 4.3, this SECTION 5.2, ARTICLE VI (other than SECTION 6.1) and all applicable defined terms, which shall remain in full force and effect) shall forthwith become wholly void and of no further force and
effect; provided that nothing herein shall relieve any party from liability for willful breach of this Agreement. 

  
 20 

 ARTICLE VI 

MISCELLANEOUS 
 SECTION
6.1. Survival. Each of the representations and warranties set forth in this Agreement shall survive the Closing under this Agreement but only for a period of twenty-four (24) months following the Closing Date, except for Fundamental
Representations which shall survive for the duration of any statutes of limitations applicable thereto, in each case or until final resolution of any claim or action arising from the breach of any such representation and warranty (including any
Fundamental Representations), if notice of such breach was provided prior to the end of such period, and thereafter shall expire and have no further force and effect. Except as otherwise provided herein, all covenants and agreements contained herein
shall survive for the duration of any statutes of limitations applicable thereto or until, by their respective terms, they are no longer operative. 

SECTION 6.2. Amendment. No amendment or waiver of this Agreement will be effective with respect to any party unless made in writing and
signed by an officer of a duly authorized representative of such party. 
 SECTION 6.3. Waivers. No failure or delay by any party in
exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The
conditions to each party’s obligation to consummate the Closing are for the sole benefit of such party and may be waived by such party in whole or in part to the extent permitted by applicable law. No waiver of any party to this Agreement will
be effective unless it is in a writing signed by a duly authorized officer of the waiving party that makes express reference to the provision or provisions subject to such waiver. 

SECTION 6.4. Counterparts. For the convenience of the parties hereto, this Agreement may be executed in any number of separate
counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts will together constitute the same agreement. Copies of executed signature pages to this Agreement may be delivered by facsimile or electronic
mail (“e-mail”) and such copies will be deemed as sufficient as if actual signature pages had been delivered. 

SECTION 6.5. Governing Law. This Agreement shall be governed by, and construed in accordance with, the law of the State of New York,
without regard to conflict of law principles. 
 SECTION 6.6. Dispute Resolution. Each of the parties hereto irrevocably
submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating
to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for
the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the 

  
 21 

 
laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any
claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. To the extent that the Company has or hereafter may acquire any immunity (on the grounds of sovereignty or otherwise) from the
jurisdiction of any court or from any legal process with respect to itself or its property, the Company irrevocably waives, to the fullest extent permitted by law, such immunity in respect of any such suit, action or proceeding. EACH OF THE PARTIES
HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

SECTION 6.7. Notices. Any notice, request, instruction or other document to be given hereunder by any party to the other will be in
writing and will be deemed to have been duly given (a) on the date of delivery if delivered personally, or upon confirmation of receipt if delivered by facsimile or e-mail, (b) on the first business
day following the date of dispatch if delivered by a recognized next-day courier service, or (c) on the third business day following the date of mailing if delivered by registered or certified mail,
return receipt requested, postage prepaid. All notices hereunder shall be delivered as follows: 
  

	 	(a)	If to the Investor: 

 Perceptive Life Sciences Master Funds, Ltd. 

51 Astor Place, 10th Floor 

New York, NY 100 

Attn: Adam Stone 

E-mail: Adam@perspectivelife.com 

with a copy (which shall not constitute notice) to: 

Tannenbaum Helpern Syracuse Hirschtritt LLP 

900 Third Avenue 

New York, NY 10022 

Attn: David R. Lallouz 

Tel: (212)702-3142 

Facsimile: (646)390-7005 

Email: lallouz@thsh.com 
  

	 	(b)	If to the Company: 

 Athenex, Inc. 

Conventus Building, 1001 Main Street, Suite 600, Buffalo, NY 14203, 

United States of America 

Attn: Teresa Bair, Vice President, Legal Affairs & Corporate Development 

Email: tbair@athenex.com 

Facsimile: +1 716 800 6818 

  
 22 

 with a copy (which shall not constitute notice) to: 

Simpson Thacher & Bartlett LLP 

ICBC Tower, 35/F 

3 Garden Road, Central 

Hong Kong SAR 

Attn: Daniel Fertig / Ian C. Ho 

Facsimile: +852 2689-7694 / +852 2514-7685 

E-mail: dfertig@stblaw.com / iho@stblaw.com 

SECTION 6.8. Entire Agreement, Etc. This Agreement (together with all the Exhibits and Schedules hereto and certificates and
other written instruments delivered in connection from time to time on and following the date hereof) constitute and contain the entire agreement and understanding of the parties with respect to the subject matter hereof and thereof, and supersedes
any and all prior negotiations, correspondence, agreements, understandings, duties and obligations between the parties with respect to the subject matter hereof and thereof. Except as expressly set forth in this Agreement, neither Party makes any
representation, warranty, covenant or agreement to the other Party of any nature, express or implied. Each party expressly represents that it is not relying on any oral or written representation, warranties, covenants or agreements other than those
expressly contained in this Agreement (which includes all Exhibits and Schedules hereto). The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and their
permitted assigns. Neither this Agreement nor any of the rights, duties or obligations hereunder may be assigned by any party hereto without the prior express written consent of the other party hereto. Any purported assignment in violation of this
SECTION 6.8 shall be null and void. 
 SECTION 6.9. Definitions. For purposes hereof, terms, when used herein with initial capital
letters, shall have the respective meanings given to them in the respective Sections set forth in the index of defined terms at the beginning of this Agreement. Wherever required by the context of this Agreement, the singular shall include the
plural and vice versa, and the masculine gender shall include the feminine and neuter genders and vice versa, and references to any agreement, document or instrument shall be deemed to refer to such agreement, document or instrument as amended,
supplemented or modified from time to time. All article, section, paragraph or clause references not attributed to a particular document shall be references to such parts of this Agreement, and all exhibit, annex and schedule references not
attributed to a particular document shall be references to such exhibits, annexes and schedules to this Agreement. 
 (a) When used herein:

 (i) the term “Affiliate” means, with respect to any person, any person directly or indirectly
controlling, controlled by or under common control with, such other person. For purposes of this definition, “control” (including, with correlative meanings, the terms “controlled by” and “under common
control with”) when used with respect to any person, means the possession, directly or indirectly, of the power to cause the direction of management and/or policies of such person, whether through the ownership of voting securities by
contract or otherwise; 

  
 23 

 (ii) the words “including,” “includes,”
“included” and “include” are deemed to be followed by the words “without limitation”; 

(iii) the terms “herein,” “hereof” and “hereunder” and other words of
similar import refer to this Agreement as a whole and not to any particular section, paragraph or subdivision; and 
 (iv)
the words “it” or “its” are deemed to mean “him” or “her” and “his” or “her,” as applicable, when referring to an individual. 

(b) The following terms shall have the following meanings: 

(i) “business day” means any day except Saturday, Sunday and any day which shall be a legal holiday or a day
on which banking institutions in the State of New York generally are authorized or required by law or other governmental actions to close; 

(ii) “person” has the meaning given to it in Section 3(a)(9) of the Exchange Act and as used in
Sections 13(d)(3) and 14(d)(2) of the Exchange Act; 
 (iii) “Beneficially Own” and “Beneficial
Ownership” are defined in Rules 13d-3 and 13d-5 of the Exchange Act; 

(iv) “Group Companies” means the Company and all of its material subsidiaries, material consolidated
affiliated entities and their material subsidiaries (individually, a “Group Company” collectively, the “Group Companies”); 

(v) “knowledge of the Company” or “Company’s knowledge” means the actual knowledge,
after due inquiry, of the executive officers of the Company; and 
 (vi) “Material Adverse Effect” means any
development, fact, circumstance, condition, event change, occurrence or effect that would have or would reasonably be expected to have a material adverse effect on the assets, business, financial condition or results of operations of the Group
Companies, taken as a whole, other than any development, fact, circumstance, condition, event, change, occurrence or effect resulting from (A) changes in general economic, financial market, business or geopolitical conditions; (B) changes
or developments in any of the industries in which the Company or any other Group Company operates; (C) changes in any applicable laws or applicable accounting regulations or principles, or the interpretation or enforcement thereof; (D) any
change in the price or trading volume of the Common Stock or any failure to meet any financial projections, forecasts or forward looking statements; (E) natural disaster or any outbreak or escalation of hostilities or war or any act of
terrorism; (F) the announcement of and performance of this Agreement by the Company, the 

  
 24 

 
pendency or consummation of the transactions contemplated hereunder, or the identity of the Investor or any of its affiliates; or (G) any action taken, or omission to take action, by the
Company or another Group Company that taking or omitting of which, as applicable, the Investor has consented to or requested in writing, provided, however, that any event, occurrence, fact, condition or change referred to in clauses (A) through
(C) and (E) above shall be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur to the extent that such event, occurrence, fact, condition or change has a disproportionate
effect on the Group Companies (taken as a whole) compared to other participants in the industries in which the Group Companies operate. 

SECTION 6.10. Captions. The article, section, paragraph and clause captions herein are for convenience of reference only, do not
constitute part of this Agreement and will not be deemed to limit or otherwise affect any of the provisions hereof. 
 SECTION 6.11.
Severability. If any provision of this Agreement is found to be invalid or unenforceable, then such provision shall be construed, to the extent feasible, so as to render the provision enforceable and to provide for the consummation of the
transactions contemplated hereby on substantially the same terms as originally set forth herein, and if no feasible interpretation would save such provision, it shall be severed from the remainder of this Agreement, which shall remain in full force
and effect unless the severed provision is essential to the rights or benefits intended by the parties. In such event, the parties shall use commercially reasonable efforts to negotiate, in good faith, a substitute, valid and enforceable provision.

 SECTION 6.12. No Third-Party Beneficiaries. Nothing contained in this Agreement, expressed or implied, is intended to confer or
shall confer upon any person other than the express parties hereto, any benefit, right or remedies. The representations and warranties set forth in Article II and the covenants set forth in Articles III and IV have been made solely for the benefit
of the parties to this Agreement and (a) may be intended not as statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; and (b) may apply standards of materiality in
a way that is different from what may be viewed as material by shareholders of, or other investors in, the Company. 
 SECTION 6.13.
Public Announcements. Without limiting any other provision of this Agreement, the parties hereto, to the extent permitted by applicable law, will consult with each other before issuance, and provide each other the opportunity to review,
comment upon and agree on any press release or public statement with respect to this Agreement (which includes the Exhibits hereto) and the transactions contemplated hereby and the ongoing business relationship among the parties hereto and thereto.
The parties hereto will not issue any such press release or make any such public statement without the prior written consent of the other party, except as may be required by law or any listing agreement with or requirement of the NASDAQ or any other
applicable securities exchange, provided that the disclosing party shall, to the extent permitted by applicable law or any listing agreement with or requirement of the NASDAQ or any other applicable securities exchange, inform the other party about
the disclosure to be made pursuant to such requirements prior to the disclosure. 

  
 25 

 SECTION 6.14. Specific Performance. The parties hereto acknowledge and agree that
irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms. It is accordingly agreed that the parties shall be entitled to seek specific performance of the
terms hereof, this being in addition to any other remedies to which they are entitled at law or equity. 

  
 26 

 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly
authorized officers of the parties hereto as of the date first herein above written. 
  

			
	ATHENEX, INC.
		
	By:	 	  

		 	Name:
		 	Title:

 [Signature Page to Share Purchase Agreement] 

 
			
	PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
		
	By:	 	  

		 	Name:
		 	Title:

 [Signature Page to Share Purchase Agreement] 

 EXHIBIT A: Form of Officer’s Certificate from the Company 

OFFICER’S CERTIFICATE 

[•], 2018 
 The undersigned,
the                                  of Athenex Inc., a company organized under the State
of Delaware (the “Company”), pursuant to SECTION 1.4(a)(v) of the Share Purchase Agreement, dated as of [•], 2018 (the “Agreement”) by and between Perceptive Life Sciences Master Fund, Ltd. (the
“Investor”) and the Company, hereby certifies to the Investor that: 
 1. The Company has performed in all material respects
all obligations required to be performed by it at or prior to or contemporaneously with the Closing under the Agreement. 
 2. The
representations and warranties of the Company set forth in SECTION 2.1 of the Agreement were true and correct in all material respects as of the date of the Agreement and are true and correct in all material respects as of the Closing (except
(i) to the extent such representations and warranties are made as of a specified date, in which case such representations and warranties shall be true and correct in all material respects as of such date and (ii) any representations and
warranties that have “material” or “Material Adverse Effect” qualifications, in which case such representations and warranties shall be true in all respects). 

Capitalized terms used but not defined herein shall have the meanings given to such terms in the Agreement. 

[Signature Page Follows] 

  
 Exhibit A – 1

 IN WITNESS WHEREOF, the undersigned has executed and delivered this certificate solely in such
respective capacity and not in an individual capacity as of this      day of                     , 2018. 

 

			
	By:	 	  

		 	Name:
		 	Title:

  
 Exhibit A – 2

 Exhibit B: Form of Legal Opinion 

  
 Exhibit B 

 Exhibit C: Form of Registration Rights Agreement 

  
 Exhibit C

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]